evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,703 questions · 15,007 findings · 1,416 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2,881 · 19.2%GRADE not reported 1,551 · 10.3%Very low 3,111 · 20.7%Low 3,881 · 25.9%Moderate 2,669 · 17.8%High 914 · 6.1%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings table ‐ Cannabis vs placebo

Specific AEs: number of participants reporting drug tolerance ( · health problem or population

It is very uncertain whether summary of findings table ‐ Cannabis changes specific AEs: number of participants reporting drug tolerance ( compared with placebo (very low certainty).

1 finding from 1 review

Tocilizumab every 4 weeks vs placebo

Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab every 4 weeks probably leads to higher proportion of participants with sustained remission (as defined by… compared with placebo (moderate certainty).

1 finding from 1 review

Tocilizumab every 4 weeks vs placebo

Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab every 4 weeks showed no clear difference in adverse events at ≥ 12 months compared with placebo (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 52‐week taper

Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly probably leads to higher proportion of participants with sustained remission (as defined by… compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 52‐week taper

Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly probably leads to higher proportion of participants with relapse‐free survival at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 52‐week taper

Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly probably leads to higher proportion of participants who did not need escape therapy (as… compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 52‐week taper

QoL · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly probably leads to higher mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 52‐week taper

Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly probably leads to higher mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 52‐week taper

Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab every 4 weeks vs placebo

Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab every 4 weeks probably leads to higher proportion of participants with relapse‐free survival at ≥ 12 months compared with placebo (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 52‐week taper

Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly showed no clear difference in adverse events at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 26‐week taper

Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly probably leads to higher proportion of participants with sustained remission (as defined by… compared with placebo + 26‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 26‐week taper

Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly probably leads to higher proportion of participants with relapse‐free survival at ≥ 12 months compared with placebo + 26‐week taper (moderate certainty).

1 finding from 1 review